Company / Total Debt
Royalty Pharma plc Total Debt History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$9.0B
FY2025
5-year range
$6.1B / $9.0B
FY2021-FY2025
Trend
+17.6%
vs FY2024
Sector context
#13 of 83
Health Care
What the data says
Royalty Pharma plc's total debt of $9.0B is higher than 84% of companies in the Health Care sector (FY2025). Total Debt has fluctuated over the past 7 years, ranging from $5.8B in FY2020 to $9.0B in FY2025.
Based on SEC 10-K filings.
$9.0B in FY2025 with a 5-year CAGR of +9.0%. Top quartile in the Health Care sector.
Increased from $6.1B to $9.0B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- +7.9%
- 5-Year CAGR
- +9.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 83This company $9.0B Sector average $6.2B
▼
+45.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, total debt increased 17.6% year-over-year.
- Ranks #13 out of 83 companies in the Health Care sector.
- Lowest total debt in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.0B | +17.6% |
| FY2024 | $7.6B | +24.1% |
| FY2023 | $6.1B | -13.8% |
| FY2022 | $7.1B | +0.3% |
| FY2021 | $7.1B | +22.0% |
| FY2020 | $5.8B | -2.3% |
| FY2019 | $6.0B | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026